Table 1.

Demographic and clinicopathologic characteristics of patients that received CART.

Variables	Allo-SCT	Non-Allo	p-Value
No. of patients	8 (14.3%)	48 (85.7%)
Male (%)	5 (62.5%)	27 (56.2%)	0.7
Median age in yrs (IQR)	57.9 (53.2–66.3)	70.6 (65.1–76.6)	0.02
Median prior LOT (range)	7 (5–11)	5 (4–12)	0.04
Median time from diagnosis to CAR-T in yrs (IQR)	13.0 (7.5–15.3)	7.7 (4.8–10.2)	0.03
High Risk FISH (%)	3 (50%)	25 (59.5%)	0.7
ISS stage II or III (%)	4 (50%)	21 (63.6%)	0.48
Triple refractory (%)	8 (100%)	44 (91.7%)	0.3
CRS (any grade)	7 (87.5%)	37 (77.1%)	0.48
CRS (GIII or higher)	0 (0%)	1 (2.1%)	0.6
ICANS (any grade)	0 (0%)	7 (14.6%)	0.1
ICANS (GIII or higher)	0 (0%)	3 (6.3%)	0.3
ORR (%)	7 (87.5%)	36 (75%)	0.4
VGPR or better (%)	6 (75%)	37(57.5%)	0.3
Median PFS (months)	Not Reached	11.9	0.5

IQR = interquartile range; LOT = lines of treatment; ISS = international staging system; CRS = cytokine release syndrome; GIII = grade III; ICANS = immune effector cell neurotoxicity syndrome; ORR = overall response rate; VGPR = very good partial remission; PFS = progression-free survival.